Coherus Biosciences
Coherus Biosciences
CHRS
NASDAQ
0.98
USD
0.00%
About
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors.
CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.6M |
| Three Month Average Volume | 36.6M |
| High Low | |
| Fifty-Two Week High | 5.465 USD |
| Fifty-Two Week Low | 1.2 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 19 Aug 2024 |
| Price and Volume | |
| Current Price | 1.39 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -2.54% |
| Thirteen Week Relative Price Change | -28.64% |
| Twenty-Six Week Relative Price Change | -47.54% |
| Fifty-Two Week Relative Price Change | -79.19% |
| Year-to-Date Relative Price Change | -64.75% |
| Price Change | |
| One Day Price Change | -2.11% |
| Thirteen Week Price Change | -23.63% |
| Twenty-Six Week Price Change | -42.32% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -73.92% |
| Year-to-Date Price Change | -58.26% |
| Month-to-Date Price Change | -9.74% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -1.7237 USD |
| Book Value Per Share (Most Recent Quarter) | -0.73011 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -2.36241 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -1.2115 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.29351 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.73191 USD |
| Revenue Per Share (Trailing Twelve Months) | 2.73955 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.52639 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.40141 USD |
| Normalized (Last Fiscal Year) | -2.45737 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.52639 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.31804 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.52639 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.40141 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.0493 USD |
| Cash Per Share (Most Recent Quarter) | 1.38231 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.48613 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.21946 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.4828 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -17 |
| Cash Flow Revenue (Trailing Twelve Months) | -18 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -9.65% |
| Pretax Margin (Last Fiscal Year) | -92.62% |
| Pretax Margin (5 Year) | -36.19% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 38.19% |
| Gross Margin (Trailing Twelve Months) | 41.51% |
| Gross Margin (5 Year) | 79.01% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -78.99% |
| Operating Margin (Trailing Twelve Months) | 0.38% |
| Operating Margin (5 Year) | -28.65% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -92.48% |
| Net Profit Margin (Trailing Twelve Months) | -9.52% |
| Net Profit Margin (5 Year) | -36.56% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 10.67% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 69.37% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -18.54% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -18.37% |
| Total Debt (5 Year) | 35.70% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 77.09% |
| EPS Change (Trailing Twelve Months) | 87.90% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 104.9M |
| Net Debt (Last Fiscal Year) | 356.7M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 15 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 8 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -175,170,000 |
| Free Cash Flow (Trailing Twelve Months) | -54,303,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -5 |
| Net Interest Coverage (Trailing Twelve Months) | -4 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -42.85% |
| Return on Assets (Trailing Twelve Months) | -5.13% |
| Return on Assets (5 Year) | -21.43% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -258.00% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -74.34% |
| Return on Investment (Trailing Twelve Months) | -11.46% |
| Return on Investment (5 Year) | -29.32% |